The British journal of radiology · 2026
Low-intensity induction chemotherapy before chemoradiotherapy for rectal cancer: 10-year overall survival in the LARC-RRP trial.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ree Anne Hansen, Meltzer Sebastian, Flatmark Kjersti, Dueland Svein
Аннотация
OBJECTIVES: Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC) often uses intensive oxaliplatin-based chemotherapy alongside standard radiotherapy to prevent metastatic progression. The optimal intensity of the chemotherapy component, given a contribution of radiotherapy to clonogenic cell elimination in the primary tumor, remains uncertain. We aimed to assess long-term outcomes of a TNT regimen with low-intensity induction chemotherapy before chemoradiotherapy, as evaluated in the LARC-RRP trial.
METHODS: Between 2005 and 2010, 87 LARC patients (36% with T4 organ-infiltrating tumor) were enrolled in the single-arm trial. Induction chemotherapy was given over 4 weeks prior to chemoradiotherapy and surgery. We report 10-year overall survival by tumor regression grade (TRG) and performed descriptive comparisons with contemporary trials whose experimental TNT arms used more intensive chemotherapy.
RESULTS: At 10 years, overall survival was 83% (95% confidence interval, 71-90) for patients with complete or near-complete tumor cell elimination in the surgical specimen (TRG 1-2; 70% of the cohort) versus 52% (95% confidence interval, 31-69) for others (log-rank P = .0005). LARC-RRP survival outcomes were comparable with those reported in more contemporary TNT trials.
CONCLUSIONS: The LARC-RRP results raise the possibility that shorter-duration chemotherapy combined with standard radiotherapy may suffice to protect against systemic recurrence of high-risk LARC.
ADVANCES IN KNOWLEDGE: These long-term data support investigation of less intensive chemotherapy within TNT regimens and may guide the design of risk-stratified TNT trials.
METHODS: Between 2005 and 2010, 87 LARC patients (36% with T4 organ-infiltrating tumor) were enrolled in the single-arm trial. Induction chemotherapy was given over 4 weeks prior to chemoradiotherapy and surgery. We report 10-year overall survival by tumor regression grade (TRG) and performed descriptive comparisons with contemporary trials whose experimental TNT arms used more intensive chemotherapy.
RESULTS: At 10 years, overall survival was 83% (95% confidence interval, 71-90) for patients with complete or near-complete tumor cell elimination in the surgical specimen (TRG 1-2; 70% of the cohort) versus 52% (95% confidence interval, 31-69) for others (log-rank P = .0005). LARC-RRP survival outcomes were comparable with those reported in more contemporary TNT trials.
CONCLUSIONS: The LARC-RRP results raise the possibility that shorter-duration chemotherapy combined with standard radiotherapy may suffice to protect against systemic recurrence of high-risk LARC.
ADVANCES IN KNOWLEDGE: These long-term data support investigation of less intensive chemotherapy within TNT regimens and may guide the design of risk-stratified TNT trials.